ISB-Laurus Labs ink pact to back technology commercialisation for scientists

June 04, 2013 11:57 pm | Updated October 18, 2016 01:13 pm IST - HYDERABAD:

ISB deputy dean Deepak Chandra (left) looks on as dean Ajit Rangnekar and Laurus Labs CEO Dr. satyanarayana Chava exchange shake hands after signing the MoU on the 'Technology Commercialisation' programme in Hyderabad on Tuesday. -Photo: Mohammmed Yousuf

ISB deputy dean Deepak Chandra (left) looks on as dean Ajit Rangnekar and Laurus Labs CEO Dr. satyanarayana Chava exchange shake hands after signing the MoU on the 'Technology Commercialisation' programme in Hyderabad on Tuesday. -Photo: Mohammmed Yousuf

Pharma firm Laurus Labs on Tuesday signed a Memorandum of Understanding with the Indian School of Business (ISB), making a one-time contribution of Rs. 30 lakh to support a ‘Technology Commercialisation’ programme for scientists across agriculture, pharma, IT, BT and manufacturing sectors.

At a press conference, Deputy Dean of ISB, Deepak Chandra announced the contribution from CEO of Laurus Labs, Satyanarayana Chava, an alumnus of its Post-Graduate Programme for Senior Executives (PGPMAX). This was the largest individual alumni grant from an alumnus, he said.

The first module of the four-module programme of four days each will begin on July 29.

Mr. Deepak Chandra said the ISB facilitated focussed work on entrepreneurship and innovation through the Wadhwani Centre for Entrepreneurship Development and the Biocon Cell for Innovation Management. Scientists working on innovative technologies now had a new opportunity to go back to the classroom.

“Today, scientists in laboratories are coming out with innovative technologies. But there is a gap between the technologies and its commercialisation that our new programmes seek to bridge,” he added.

Mr. Satyanarayana Chava said Laurus Labs, that registered a turnover of Rs. 720 crore in the last fiscal, spent about six per cent of revenues on research and development. It was focussed on active pharmaceutical ingredients on anti-retroviral drugs for HIV and on oncology, he said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.